Automated – Consistent – Reliable – Fast
Our automated selection systems using the latest high-throughput technologies allow us to offer rapid development of aptamers with unparalleled precision and accuracy.
We offer a staged platform for aptamer development, offering the user explicit control over the process.
Phase 1 – Stability and Feasibility Studies – 2-3 weeks
Aptamer Group allows confirmation of whether a high-affinity aptamer will be able to be raised to your target within two weeks of the project beginning.
Phase 2 – Polyclonal Aptamer Selection – 6-8 weeks
Using our high-throughput platform, we aim to complete aptamer selection in as little as 6 weeks.
Phase 3 – Polyclonal Aptamer Characterisation – 1-2 weeks
Aptamers produced are profiled using functional assays in the appropriate buffer/matrix.
Phase 4 – Monoclonal Aptamer Identification – 2-4 weeks
This process converts a ‘polyclonal’ aptamer mix into a list of ‘monoclonal’ aptamers. Individual aptamers are assessed for target affinity.
To read more about our rapid development and expertise, click here.